Russell LaMontagne

Russell LaMontagne is the President and CEO of Boston Immune Technologies and Therapeutics (BITT), a biopharmaceutical company focused on developing immune-based approaches for treating cancer and infectious diseases.1

Professional Background

LaMontagne has extensive experience in the healthcare industry, spanning over 20 years.1 His career has primarily involved consulting roles with various organizations, including:

• Biotechnology companies
• Non-profit organizations
• University of Pennsylvania
• New England Journal of Medicine
• VIRxSYS
• Bristol-Myers Squibb

Before co-founding BITT, LaMontagne served as the president of Corinth Group, a boutique healthcare consultancy.1

Education

• BS in Biology from the University of Massachusetts at Amherst
• MS from Yale University1

Role at BITT

As the co-founder and CEO of BITT, LaMontagne oversees all aspects of the company's growth and development.4 Under his leadership, BITT has made significant strides in developing novel TNF Superfamily antagonist antibodies.2

Recent Achievements

In March 2021, LaMontagne led BITT through a successful Series A/A1 preferred stock financing round, raising $10 million.2 This funding, combined with a partnership with BeiGene, has provided BITT with the resources to advance their lead candidate, BIR2101, into clinical trials.2

Research Focus

BITT, under LaMontagne's guidance, is exploring clinical trials for BIR2101, a novel TNFR2 antagonist antibody, both as a monotherapy and in combination with checkpoint blockade for oncology and infectious disease indications.2 The company is also developing additional TNF Superfamily antagonist antibodies for various applications in oncology, inflammation, autoimmunity, and infectious diseases.2

Russell LaMontagne's LinkedIn profile can be found under the username russell-lamontagne-2bb1a3, where he has 2,000 followers and over 500 connections.3